3 Oleochemical Additives Maker, Garment Exporter for Global Brands and Respiratory Medicines Company Stocks With a Strong Future Roadmap: Fine Organic Industries, Pearl Global Industries and Cipla
- November 2, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Fine Organic Industries, Pearl Global Industries and Cipla: ROE of 11.3% to 19.0% and FY22 to FY26 revenue CAGR of 6.8% to 16.5%. Prices as of 30 Oct 2026.
Quick Answer
The three additive, garment exporter and drug stocks to watch are Fine Organic Industries, Pearl Global Industries and Cipla. Their return on equity ranges from 11.3% to 19.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 16.5%. Pearl Global Industries leads on both return on equity at 19.0% and revenue growth at 16.5% a year. Prices are based on the 30 October 2026 close, and this article is educational, not investment advice.
Additive, garment exporter and drug stocks offer a focused view of a sector where demand keeps widening. Fine Organic Industries, Pearl Global Industries and Cipla cover an oleochemical additives maker, a garment exporter for global brands and a respiratory medicines company.
This list covers three additive, garment exporter and drug stocks with complete current figures: Fine Organic Industries, Pearl Global Industries and Cipla. Every figure comes from the latest reported financials and the 30 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Additive, Garment Exporter and Drug Stocks?
Additive, garment exporter and drug stocks are listed companies that make oleochemical based additives for food, plastics and cosmetics, produce garments for leading international brands, and sell respiratory, anti infective and chronic care medicines in India and overseas. Their earnings depend on export orders, product mix and input costs.
Additive, Garment Exporter and Drug Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Fine Organic Industries | 5,049 | 16,561 | 37.8 | 35.1 | 15.7 | 0.03 |
| Pearl Global Industries | 1,192.6 | 11,806 | 38.9 | 35.2 | 19.0 | 0.65 |
| Cipla | 1,378.9 | 107,528 | 32.0 | 36.0 | 11.3 | 0.02 |
On valuation, Cipla trades at a P/E below the industry P/E, while Fine Organic Industries and Pearl Global Industries trade above it, which reflects the growth the market already expects. Readers comparing additive, garment exporter and drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in additive, garment exporter and drug stocks can use the coming numbers to test whether growth is holding.
Why Do Additive, Garment Exporter and Drug Stocks Have a Strong Roadmap in India?
Additive, garment exporter and drug stocks have a strong roadmap in India because niche chemistry leadership, global brands diversifying sourcing and steady demand for chronic care medicines keep widening the market for these export focused companies.
- Niche additives. Leading products support pricing strength.
- Sourcing shift. Global brands add Indian factories.
- Chronic care. Respiratory medicines bring repeat use.
Why Fine Organic Industries Features Among These Additive, Garment Exporter and Drug Stocks
Among the additive, garment exporter and drug stocks on this list, Fine Organic Industries is a leading maker of oleochemical-based additives used in food, plastics, cosmetics and coatings, selling to customers in India and overseas.
Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%.
In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1.
Roadmap: The company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.
What to watch: Monitor raw material prices, export demand and the pace of new capacity addition.
Why Pearl Global Industries Features Among These Additive, Garment Exporter and Drug Stocks
Among the export oriented shares on this list, Pearl Global Industries is a Gurugram-based apparel manufacturer and exporter that makes garments for leading international brands from factories in India, Bangladesh, Vietnam and Indonesia.
In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore. Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%.
Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2.
Roadmap: The company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.
What to watch: Watch order inflow from global brands and the ramp-up of newer factories.
Why Cipla Features Among These Additive, Garment Exporter and Drug Stocks
Among the three companies on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.
The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.
Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore.
Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
What to watch: Follow new product launches in the United States and the growth of key domestic brands.
Fine Organic Industries vs Pearl Global Industries vs Cipla on Key Financials
The table below sets the three additive, garment exporter and drug stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Fine Organic Industries | 1,909 | 2,482 | 6.8% | 417 | 16.8% |
| Pearl Global Industries | 2,747 | 5,062 | 16.5% | 270 | 5.3% |
| Cipla | 22,044 | 29,045 | 7.1% | 3,870 | 13.3% |
Pearl Global Industries posts the highest return on equity in this group at 19.0%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Pearl Global Industries shows the fastest revenue growth with a 16.5% compound annual rate. A useful habit with additive, garment exporter and drug stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several chemical, garment and drug exporters instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Fine Organic Industries | 628 | 718 | 14.4% |
| Pearl Global Industries | 1,239 | 1,539 | 24.2% |
| Cipla | 7,216 | 7,330 | 1.6% |
Key Risks to Check Before Investing in Additive, Garment Exporter and Drug Stocks
Every theme carries risks that deserve a check before any decision. For these additive, garment exporter and drug stocks, the main points are: Long-term export oriented shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Currency moves. Export earnings move with the rupee.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter additive, garment exporter and drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Additive, Garment Exporter and Drug Stocks
Additive, garment exporter and drug stocks reward patient research into demand, execution and financial strength. Fine Organic Industries, Pearl Global Industries and Cipla each have a clear plan to grow. Based on the 30 October 2026 close, Fine Organic Industries trades at Rs 5,049, Pearl Global Industries at Rs 1,192.6 and Cipla at Rs 1,378.9. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these additive, garment exporter and drug stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track additive, garment exporter and drug stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are additive, garment exporter and drug stocks?
Ans. Additive, garment exporter and drug stocks are listed companies that make oleochemical based additives for food, plastics and cosmetics, produce garments for leading international brands, and sell respiratory, anti infective and chronic care medicines in India and overseas. Their earnings depend on export orders, product mix and input costs. This list looks at three of them, Fine Organic Industries, Pearl Global Industries and Cipla, using reported FY22 to FY26 financials and the 30 October 2026 closing prices.
Which additive, garment exporter and drug stocks are covered in this list?
Ans. This list covers Fine Organic Industries, Pearl Global Industries and Cipla. Based on the 30 October 2026 close, Fine Organic Industries traded at Rs 5,049, Pearl Global Industries at Rs 1,192.6 and Cipla at Rs 1,378.9. Their return on equity ranges from 11.3% to 19.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 16.5%.
Why do additive, garment exporter and drug stocks have a strong future roadmap in India?
Ans. Additive, garment exporter and drug stocks have a strong roadmap in India because niche chemistry leadership, global brands diversifying sourcing and steady demand for chronic care medicines keep widening the market for these export focused companies. The main drivers are as follows. Niche additives. Leading products support pricing strength. Sourcing shift. Global brands add Indian factories. Chronic care. Respiratory medicines bring repeat use. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Fine Organic Industries performed financially?
Ans. Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1. Looking ahead, the company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.
How has Pearl Global Industries performed financially?
Ans. Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%. Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore. The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2. Looking ahead, the company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.
How has Cipla performed financially?
Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
What risks should investors check before buying additive, garment exporter and drug stocks?
Ans. Investors should check a few risks before buying additive, garment exporter and drug stocks. Currency moves. Export earnings move with the rupee. Regulatory approvals. Plant inspections and approvals can affect supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of additive, garment exporter and drug stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 30 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
